E
Emilia Cantón
Researcher at Instituto Politécnico Nacional
Publications - 136
Citations - 5490
Emilia Cantón is an academic researcher from Instituto Politécnico Nacional. The author has contributed to research in topics: Candida parapsilosis & Anidulafungin. The author has an hindex of 37, co-authored 134 publications receiving 4990 citations. Previous affiliations of Emilia Cantón include University of Texas at San Antonio & Group Health Research Institute.
Papers
More filters
Journal ArticleDOI
Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study
Anna Maria Tortorano,Javier Pemán,Hannelore Bernhardt,Lena Klingspor,Christopher C. Kibbler,Odile Faure,E. Biraghi,Emilia Cantón,K. Zimmermann,S. Seaton,Renée Grillot +10 more
TL;DR: The survey results underline the burden of candidaemia in a wide range of patient populations, confirm the importance of non-albicans species, and provide baseline data for future surveillance studies at a European level.
Journal ArticleDOI
Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death.
TL;DR: Multivariate analysis indicated that neutropenia, corticosteroid therapy, lack of antifungal treatment, and failure to replace the central venous catheter were factors associated with candidemia-related death.
Journal ArticleDOI
Antifungal Susceptibility Testing of Filamentous Fungi
TL;DR: Methods developed for testing filamentous fungi (molds) include standardized broth microdilution methods and disk diffusion methods and the link between resistance molecular mechanisms, elevated MICs, and clinical treatment failure has been documented.
Journal ArticleDOI
Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Triazoles and Six Aspergillus spp. for the CLSI Broth Microdilution Method (M38-A2 Document)
Ana Espinel-Ingroff,Daniel J. Diekema,Annette W. Fothergill,Elizabeth M. Johnson,Teresa Peláez,M. A. Pfaller,Michael G. Rinaldi,Emilia Cantón,John D. Turnidge +8 more
TL;DR: Although ECVs do not predict therapy outcome as clinical breakpoints do, they may aid in detection of azole resistance (non-WT MIC) due to cyp51A mutations, a resistance mechanism in some Aspergillus spp.
Journal ArticleDOI
Cryptococcus neoformans-Cryptococcus gattii Species Complex: an International Study of Wild-Type Susceptibility Endpoint Distributions and Epidemiological Cutoff Values for Fluconazole, Itraconazole, Posaconazole, and Voriconazole
Ana Espinel-Ingroff,A.I. Aller,Emilia Cantón,Laura Rocío Castañón-Olivares,Anuradha Chowdhary,S. Cordoba,Manuel Cuenca-Estrella,A. W. Fothergill,J. Fuller,Nelesh P. Govender,Ferry Hagen,Maria-Teresa Illnait-Zaragozi,Elizabeth M. Johnson,Sarah E. Kidd,Cornelia Lass-Flörl,Shawn R. Lockhart,Marilena dos Anjos Martins,Jacques F. Meis,M.S. Melhem,Luis Ostrosky-Zeichner,Teresa Peláez,Michael A. Pfaller,Wiley A. Schell,G. St-Germain,Luciana Trilles,John D. Turnidge +25 more
TL;DR: In the absence of clinical breakpoints, the authors' ECVs may aid in the detection of isolates with acquired resistance mechanisms and should be listed in the revised CLSI M27-A3 and CLSIM27-S3 documents.